ADAM9 Protein, Cynomolgus, Recombinant (His)

产品编号 TMPK-00553

A disintegrin and metalloproteinase 9 (ADAM9) is a member of the transmembrane ADAM family. It is expressed in different types of solid cancer and promotes tumor invasiveness. ADAM9 may be a prognostic marker for vestibular schwannomas (VS), and ADAM9 inhibition might have the potential as a systemic approach for the treatment of VS.

ADAM9 Protein, Cynomolgus, Recombinant (His)

产品编号 TMPK-00553

规格	价格	库存
100 μg	¥ 3,100	5日内发货
500 μg	¥ 12,400	5日内发货
1 mg	¥ 20,700	5日内发货

大包装 & 定制

加入购物车

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

实验操作小课堂

常见问题解答

资源下载

重组蛋白用户指南

产品信息

生物活性	Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
产品描述	A disintegrin and metalloproteinase 9 (ADAM9) is a member of the transmembrane ADAM family. It is expressed in different types of solid cancer and promotes tumor invasiveness. ADAM9 may be a prognostic marker for vestibular schwannomas (VS), and ADAM9 inhibition might have the potential as a systemic approach for the treatment of VS.
种属	Cynomolgus
表达系统	HEK293 Cells
标签	C-His
蛋白编号	A0A2K5X4X8
别名	Mltng,mKIAA0021,Meltrin-γ,Meltrin-gamma,Mdc9,MCMP,Kiaa0021,CORD9,AU020942,Adam9,ADAM 9
蛋白构建	Ala29-Gly698
蛋白纯度	> 90% as determined by Tris-Bis PAGE; > 90% as determined by HPLC
分子量	74.90 kDa (predicted). The protein migrates to 65-115 kDa based on Tris-Bis PAGE result.
内毒素	< 1 EU/μg by the LAL method.
缓冲液	Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
存储	It is recommended to store the product under sterile conditions at -70°C or lower. Samples are stable for up to 12 months at -80°C. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.
研究背景	A disintegrin and metalloproteinase 9 (ADAM9) is a member of the transmembrane ADAM family. It is expressed in different types of solid cancer and promotes tumor invasiveness. ADAM9 may be a prognostic marker for vestibular schwannomas (VS), and ADAM9 inhibition might have the potential as a systemic approach for the treatment of VS.